MX2022016270A - Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma. - Google Patents

Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.

Info

Publication number
MX2022016270A
MX2022016270A MX2022016270A MX2022016270A MX2022016270A MX 2022016270 A MX2022016270 A MX 2022016270A MX 2022016270 A MX2022016270 A MX 2022016270A MX 2022016270 A MX2022016270 A MX 2022016270A MX 2022016270 A MX2022016270 A MX 2022016270A
Authority
MX
Mexico
Prior art keywords
bcl
antibody
inhibitor
combination
hodgkin
Prior art date
Application number
MX2022016270A
Other languages
English (en)
Inventor
Rainer Boxhammer
Konstantin Petropoulos
Peter Kelemen
Markus Rückert
Jan Endell
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MX2022016270A publication Critical patent/MX2022016270A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente divulgación describe una combinación farmacéutica de un anticuerpo anti-CD19 y un inhibidor de BCL-2 para el tratamiento de linfoma no Hodgkin, leucemia linfocítica crónica y/o leucemia linfoblástica aguda.
MX2022016270A 2016-10-28 2019-04-26 Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma. MX2022016270A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16196184 2016-10-28

Publications (1)

Publication Number Publication Date
MX2022016270A true MX2022016270A (es) 2023-02-15

Family

ID=57218739

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019004942A MX2019004942A (es) 2016-10-28 2017-10-27 Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.
MX2022016270A MX2022016270A (es) 2016-10-28 2019-04-26 Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019004942A MX2019004942A (es) 2016-10-28 2017-10-27 Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.

Country Status (24)

Country Link
US (1) US20190241656A1 (es)
EP (2) EP3532098B1 (es)
JP (2) JP7094950B2 (es)
KR (2) KR102500868B1 (es)
CN (2) CN109890418B (es)
AU (1) AU2017348624B2 (es)
BR (1) BR112019008244A2 (es)
CA (1) CA3037246A1 (es)
CY (1) CY1124648T1 (es)
DK (1) DK3532098T3 (es)
ES (1) ES2871574T3 (es)
HR (1) HRP20210838T1 (es)
HU (1) HUE054496T2 (es)
IL (2) IL266216B2 (es)
LT (1) LT3532098T (es)
MX (2) MX2019004942A (es)
PL (1) PL3532098T3 (es)
PT (1) PT3532098T (es)
RS (1) RS62036B1 (es)
RU (1) RU2756405C2 (es)
SG (1) SG10202104036QA (es)
SI (1) SI3532098T1 (es)
WO (1) WO2018078123A1 (es)
ZA (1) ZA201903302B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018276384A1 (en) * 2017-05-31 2019-11-07 Incyte Corporation Treatment paradigm for an anti-CD19 antibody and venetoclax combination treatment
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
CN112638392B (zh) * 2018-08-31 2024-09-10 Adc治疗有限公司 组合疗法
CN114786723A (zh) * 2019-10-31 2022-07-22 莫佛塞斯公司 序贯抗cd19疗法
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
WO2002022212A2 (en) 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
CA2534639C (en) 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1899379B1 (en) 2005-06-20 2018-04-11 E. R. Squibb & Sons, L.L.C. Cd19 antibodies and their uses
EP2270050B1 (en) 2005-12-30 2013-06-05 Merck Patent GmbH Anti-CD19 antibodies with reduced immunogenicity
ES2402591T3 (es) 2006-08-14 2013-05-07 Xencor Inc. Anticuerpos optimizados que seleccionan como diana CD19
EP2066349B1 (en) 2006-09-08 2012-03-28 MedImmune, LLC Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases
EP2708557A1 (en) 2007-05-30 2014-03-19 Xencor, Inc. Method and compositions for inhibiting CD32B expressing cells
LT2211904T (lt) 2007-10-19 2016-11-25 Seattle Genetics, Inc. Cd19 surišantys agentai ir jų panaudojimas
US8679492B2 (en) 2009-02-23 2014-03-25 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to CD19 and their uses
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010151341A1 (en) 2009-06-24 2010-12-29 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
KR20200058583A (ko) * 2011-08-16 2020-05-27 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
HUE058855T2 (hu) * 2011-08-16 2022-09-28 Morphosys Ag Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásával
EP3476392A1 (en) * 2014-02-28 2019-05-01 Merck Sharp & Dohme Corp. Method for treating cancer
CA2972827A1 (en) 2015-02-12 2016-08-18 Seattle Genetics, Inc. Combination therapy using a cd19-adc and vincristine

Also Published As

Publication number Publication date
IL301786A (en) 2023-05-01
MX2019004942A (es) 2019-08-12
CN109890418B (zh) 2024-03-08
IL266216B1 (en) 2023-05-01
RU2019113370A3 (es) 2021-03-01
BR112019008244A2 (pt) 2019-07-16
JP7094950B2 (ja) 2022-07-04
RU2756405C2 (ru) 2021-09-30
DK3532098T3 (da) 2021-05-25
PT3532098T (pt) 2021-06-17
US20190241656A1 (en) 2019-08-08
SG10202104036QA (en) 2021-05-28
IL266216B2 (en) 2023-09-01
CN109890418A (zh) 2019-06-14
EP3532098A1 (en) 2019-09-04
ES2871574T3 (es) 2021-10-29
IL266216A (en) 2019-06-30
KR20190075942A (ko) 2019-07-01
EP3532098B1 (en) 2021-04-07
KR20230028571A (ko) 2023-02-28
RU2019113370A (ru) 2020-11-30
JP2019533682A (ja) 2019-11-21
HUE054496T2 (hu) 2021-09-28
CY1124648T1 (el) 2022-07-22
EP3903821A1 (en) 2021-11-03
CA3037246A1 (en) 2018-05-03
JP2022137089A (ja) 2022-09-21
CN118045175A (zh) 2024-05-17
RS62036B1 (sr) 2021-07-30
WO2018078123A1 (en) 2018-05-03
HRP20210838T1 (hr) 2021-08-06
PL3532098T3 (pl) 2022-01-31
SI3532098T1 (sl) 2021-12-31
KR102500868B1 (ko) 2023-02-16
ZA201903302B (en) 2021-04-28
AU2017348624A1 (en) 2019-03-28
LT3532098T (lt) 2021-06-25
AU2017348624B2 (en) 2024-09-26

Similar Documents

Publication Publication Date Title
MX2022016270A (es) Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.
IL276830A (en) Anti-claudin 18.2 antibodies and uses thereof
SG11202007074PA (en) Anti-claudin 18.2 antibodies and uses thereof
EP3878863A4 (en) ANTI-CLAUDIN18.2 ANTIBODIES AND ITS USE
MX2017016851A (es) Anticuerpo para el ligando del factor 1 de muerte celular programada (pdl-1), composicion farmaceutica del mismo y uso de los mismos.
WO2016062722A8 (en) Combination
EP4360646A3 (en) Anti-tigit antibodies and methods of use
CY1122298T1 (el) Συνδυασμος αντισωματος anτι-cd19 και αναστολεα τυροσινης κινασης toy bruton και χρησεις του
PH12017501318A1 (en) Anti-transthyretin antibodies
ZA202103061B (en) Anti-cldn18.2 antibody and uses thereof
MX2019005401A (es) Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma.
WO2018081648A3 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
EP3411504A4 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USE FOR THE TREATMENT OR PREVENTION OF TYPE-1 DIABETES
MX353589B (es) Terapia de combinacion con un anticuerpo anti-cd19 y un analogo de purina.
MX2019015516A (es) Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer.
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
WO2015185875A3 (fr) Anticorps dirigé contre la galectine 9 et inhibiteur de l'activité suppressive des lymphocytes t régulateurs
MX2022006154A (es) Combinaciones y sus usos.
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
MX2013014933A (es) Terapia de combinacion con un anticuerpo anti-cd19 y una mostaza de nitrogeno.
MX2023014145A (es) Oligonucleotidos modificados y metodos de uso.
PH12021550553A1 (en) Pharmaceutical combinations for treating tumor comprising anti-cd19 antibody and natural killer cell
MY188849A (en) Combination therapy of an anti cd20 antibody with a bcl-2 inhibitor and a mdm2 inhibitor
WO2018007922A3 (en) Anti-transthyretin antibodies
WO2016170124A3 (en) Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior